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Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout. Following 3 
concerns about the cardiovascular safety of febuxostat, the European Medicines Agency (EMA) 4 
recommended a post-licensing study comparing the cardiovascular (CV) safety of febuxostat versus 5 
allopurinol.  6 
Methods 7 
We conducted a prospective, randomised, open-label, blinded endpoint (PROBE) non-inferiority trial 8 
of febuxostat versus allopurinol in patients with gout in the UK, Denmark, and Sweden. Eligible 9 
patients were 60 years or older, currently treated with allopurinol, with at least one additional 10 
cardiovascular risk factor. After increasing allopurinol dose if necessary to achieve serum urate  11 
levels < 0·357 mmol/L (< 6 mg/dL), patients were randomly assigned to continue allopurinol (at 12 
optimised dose) or start febuxostat at a dose of 80mg daily, increasing to 120mg, if necessary, to 13 
achieve serum uric acid level < 0·357 mmol/L. The primary outcome was the composite of 14 
hospitalisation for non-fatal myocardial infarction/biomarker positive acute coronary syndrome, 15 
non-fatal stroke or cardiovascular death. The hazard ratio (febuxostat versus allopurinol) in a Cox 16 
proportional hazards model was assessed for non-inferiority (limit of 1·3) in an on-treatment (OT) 17 
analysis and then by intention to treat (ITT). This study is registered with the EU Clinical Trials 18 
Register (EudraCT 2011-001883-23) and ISRCTN (ISRCTN72443728). 19 
Findings 20 
From 20 December, 2011, to 26 January, 2018, 6128 patients (mean age 71, 85·3% male, 33·4% prior 21 
CV disease) were enrolled and randomised to receive allopurinol (n=3065) or febuxostat (n=3063)) 22 
and were followed up to December 2019, during which 5·5% and 6·2% respectively withdrew from 23 
all follow up. Median follow-up time in the study was 1467 days [IQR 1029-2052] and median on-24 
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treatment follow-up period was 1324 days [IQR 870-1919]. In both the on-treatment and intention-25 
to-treat analyses, febuxostat therapy was non-inferior to allopurinol therapy for incidence of the 26 
primary endpoint (OT analysis: febuxostat 172 patients [1·72 events per 100 patient years]; 27 
allopurinol 241 patients [2·05 events per 100 patient years]; hazard ratio 0·85 [95% CI 0·70-1·03], 28 
p<0·001; ITT analysis: febuxostat 256 patients [2·05 events per 100 patient years], allopurinol 285 29 
patients [2·29 events per 100 patient years]; hazard ratio 0·89 [95% CI 0·75-1·06], p< 0·001). A total 30 
of 222 (7·2%) patients died and 1720 (57·3%) experienced at least one serious adverse event (SAE) in 31 
the febuxostat group compared to 263 deaths (8·6%) and 1812 patients with one or more SAE 32 
(59·4%) in the allopurinol group. In the febuxostat group, 973 patients [32·4%] discontinued 33 
randomised therapy compared with 503 patients [16·5%] on allopurinol. 34 
Interpretation 35 
Febuxostat was non-inferior to allopurinol therapy for the primary cardiovascular outcome. Long-36 
term use of febuxostat was not associated with an increased risk of death or serious adverse events 37 
compared with allopurinol. 38 
Funding: Menarini funded the study. Menarini received support from Ipsen and Teijin Pharma 39 
Limited. The University of Dundee was the sponsor and the funder had no involvement in the 40 
running of the study. 41 
  42 
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Research in context 43 
 44 
Evidence before this study 45 
We searched PubMed on 17 September, 2020, using the search terms “febuxostat”, “allopurinol”, 46 
and “cardiovascular outcomes”. We searched for original articles with no date or language 47 
restriction for any randomised clinical trials with >500 participants comparing febuxostat with 48 
allopurinol in terms of cardiovascular outcomes. We found one trial, the ‘Cardiovascular Safety of 49 
Febuxostat or Allopurinol in Patients with Gout (CARES)’ trial. This trial, involving 6190 randomised 50 
patients with gout and major cardiovascular coexisting conditions, reported that febuxostat was 51 
non-inferior to allopurinol with respect to rates of adverse cardiovascular events. However, the risk 52 
of death from any cause (febuxostat n=243 (7·8%), allopurinol n=199 (6·4%); HR 1·22 (95% CI 1·01-53 
1·47); p=0·04) and the risk of cardiovascular death (febuxostat n=134 (4·3%), allopurinol n=100 54 
(3·2%); HR 1·34 (95% CI 1·03-1·73); p=0·03) (modified intention to treat analysis) were higher in the 55 
febuxostat group than in the allopurinol group in CARES.  56 
Added value of this study 57 
The FAST study was a large, multicentre, prospective, randomised, open-label, blinded endpoint 58 
non-inferiority study to compare the cardiovascular safety of febuxostat versus allopurinol in 6128 59 
patients with gout and at least one additional cardiovascular risk factor, who were already treated 60 
with allopurinol. The population studied differed from that in the CARES trial. FAST participants were 61 
generally at lower cardiovascular risk than CARES participants as only about one third of patients in 62 
FAST had prior major cardiovascular comorbidity. Daily doses of febuxostat in FAST were higher 63 
(80mg or 120mg daily) than in CARES (40mg or 80 mg daily) and dose ranges of allopurinol were 64 
wider in FAST (100mg-900mg daily) than CARES (200-600mg daily). Only 5·8% of patients in FAST 65 
withdrew from all follow up, and randomised treatment discontinuation rates (16·5% in the 66 
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allopurinol group and 32·4% in the febuxostat group) were lower than in the CARES trial. In CARES, 67 
45·0% of patients did not complete all trial visits and 56·6% of patients discontinued randomised 68 
treatment prematurely. FAST used record-linkage to national healthcare databases to complement 69 
other methods of reporting for the detection of hospitalisations and deaths. We found that 70 
febuxostat was non-inferior to allopurinol for the primary composite endpoint of hospitalisation for 71 
non-fatal myocardial infarction/biomarker positive acute coronary syndrome, non-fatal stroke or 72 
cardiovascular death during a median on-treatment period of 1324 days [IQR 870, 1919] or 3·63 73 
years. In contrast to CARES, treatment with febuxostat was not associated with an increase in 74 
cardiovascular death or all-cause death in FAST, nor in the subgroup of patients in FAST with a 75 
baseline history of MI, stroke or acute coronary syndrome. Overall there were fewer deaths in the 76 
febuxostat group (62 CV deaths and 108 all-cause deaths (OT), 117 CV deaths and 222 all-cause 77 
deaths (ITT)), than in the allopurinol group (82 CV deaths and 174 all-cause deaths (OT), 122 CV 78 
deaths and 263 all-cause deaths (ITT)). 79 
Implications of all the available evidence 80 
Whilst the CARES study suggested that febuxostat therapy may be associated with higher risk of all-81 
cause mortality and cardiovascular mortality than allopurinol, the FAST study, with better 82 
ascertainment of events, found no increase in these risks.  83 
 84 




Gout is a metabolic disorder in which prolonged elevation of serum urate can lead to the deposition 87 
of crystals of monosodium urate (MSU), tophus formation, chronic inflammatory arthritis, 88 
urolithiasis, and nephropathy, as well as to recurrent flares of acute arthritis and bursitis. Gout is 89 
frequently associated with co-morbidities such as chronic kidney disease, obesity, diabetes mellitus, 90 
hypertension and cardiovascular disease and with increased mortality.1-3  In addition to treatment of 91 
acute flares with anti-inflammatory drugs, management of gout requires long term therapy with 92 
urate lowering therapy (ULT) to persistently reduce the SUA below its crystallisation threshold in 93 
order to dissolve crystal deposits, prevent further crystal deposition, recurrent flares of gout and 94 
progressive joint damage. The most widely used urate lowering medications are the xanthine 95 
oxidase inhibitors (XOI), allopurinol and febuxostat. Prophylaxis against acute flares of gout is 96 
recommended when treatment is initiated with ULT or following dose increases of a XOI, typically for 97 
a period of up to six months.4 98 
Initial clinical trials comparing febuxostat to allopurinol or placebo identified a numerically higher 99 
risk of cardiovascular events in patients taking febuxostat.5–8 Marketing authorisation for febuxostat 100 
was granted after a subsequent 6-month randomised controlled trial of febuxostat compared to 101 
allopurinol in 2269 participants (the CONFIRMS trial)9 showed equal numbers (0·4%) of adjudicated 102 
cardiovascular events with febuxostat 80mg and allopurinol, and no cardiovascular deaths in the 103 
febuxostat treated patients. However, because of lingering concerns about the possibility of 104 
increased cardiovascular risk with febuxostat, the European Union Risk Management Plan for 105 
febuxostat indicated that a post-authorisation safety study should be carried out in Europe in 106 
patients with gout to evaluate the cardiovascular effects of febuxostat versus standard urate 107 
lowering therapy with allopurinol. The Febuxostat versus Allopurinol Streamlined Trial (FAST) was 108 




Study Design and participants 111 
A prospective, randomised, open-label, blinded endpoint (PROBE) multi-centre trial was undertaken 112 
in patients with gout at 18 regional centres in three countries (UK – Scotland and England, Denmark 113 
and Sweden).10  The study protocol (appendix pp157-217) was approved by ethics committees and 114 
regulatory authorities in each country. All participants gave written informed consent. 115 
Patients were mainly recruited from 850 primary care practices in the UK and Denmark (by search of 116 
primary care records for potentially eligible patients), but also from two secondary care centres in 117 
Scotland, and via two clinical research organisations in Sweden. Eligible patients were aged 60 years 118 
or older, with  gout,11 who in the opinion of the recruiting physician required urate lowering therapy. 119 
No patients with asymptomatic hyperuricaemia were recruited to the study. Eligible participants had 120 
at least one additional cardiovascular risk factor (appendix p6) and were already receiving 121 
allopurinol therapy. Patients with a history of myocardial infarction or stroke in the previous 6 122 
months and those with congestive heart failure, New York Heart Association (NYHA) Class III or IV, or 123 
severe renal impairment were excluded. A full list of inclusion and exclusion criteria is detailed in the 124 
appendix (appendix pp4-5).  125 
Randomisation 126 
At the screening visit, serum urate was measured. If the SUA was not controlled to the European 127 
League Against Rheumatism (EULAR) target of < 0·357 mmol/L (<6mg/dL)12  on the patient’s pre-128 
study allopurinol dose, this was increased by 100mg daily every two weeks until the urate was at 129 
target or the patient reached the maximum licensed dose (900mg daily) or maximum tolerated dose 130 
of allopurinol. This dose increase was carried out because febuxostat 80mg is a more potent urate 131 
lowering therapy than low dose allopurinol. The dose increase was carried out every two weeks in all 132 
patients who were not yet at target urate, unless there were tolerability issues, or the maximum 133 
licensed dose had been reached, in which case patients could continue in the study even if the target 134 
urate had not been reached. After the allopurinol dose had been optimised to reach the target urate 135 
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level, or immediately for patients who were already controlled to target at screening, patients were 136 
randomly allocated to receive allopurinol therapy or febuxostat using a central web-based 137 
randomisation facility located at the Robertson Centre for Biostatistics, University of Glasgow. The 138 
randomisation system could be accessed via an interactive voice response system or by a web-based 139 
application. The randomisation list was created by a statistician in the Robertson Centre based 140 
on randomised permuted blocks of size four stratified according to previous cardiovascular events 141 
(myocardial infarction, stroke or hospitalisation for congestive heart failure or peripheral vascular 142 
disease). Randomised therapy was not blinded to participants, site staff and treating physicians but 143 
was blinded to the endpoint adjudication committee. 144 
Post-randomisation, while the majority of patients remained on the daily dose assigned at 145 
randomisation, the daily dose of allopurinol or febuxostat could be reduced or increased by a 146 
physician within the licensed daily dose limits based on clinical discretion, for example, reduced due 147 
to tolerability issues or increased due to inadequate control of urate levels identified during annual 148 
visits. 149 
Allopurinol was chosen as the comparator for febuxostat because it is the long-established, first-line 150 
ULT for gout. 151 
Procedures 152 
Allopurinol 100mg and 300mg tablets (Salutas Pharma GmbH, Barleben, Germany; Teva 153 
Pharmaceutical Works Private Limited company, Debrecen, Hungary) and febuxostat 80mg and 154 
120mg tablets (Patheon France, Bourgoin Jallieu, France; Menarini, Dresden, Germany) were 155 
supplied directly by post to participants from the research pharmacy at the University of Dundee 156 
(except in Sweden where they were supplied from the Dundee research pharmacy via a local 157 
pharmacy). Allopurinol was given orally at the daily dose required to control urate levels to < 0·357 158 
mmol/L or the maximum tolerated or licensed dose. Febuxostat was commenced orally at 80mg 159 
daily. After two weeks, the SUA was measured in those taking febuxostat and if not controlled to < 160 
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0·357 mmol/L, the febuxostat dose was increased to 120mg daily. All patients had a washout period 161 
of seven days (7-21 days) after randomisation before starting randomised therapy. 162 
Six months of prophylaxis against gout flares was offered to all patients at the start of randomised 163 
therapy. Prophylaxis was started earlier in any patients whose allopurinol dose was increased during 164 
the allopurinol lead-in phase and was offered again at any time during the study when a patient’s 165 
dose of ULT was increased. First-line gout flare prophylaxis was with colchicine (0·5mg once or twice 166 
daily) and second-line alternatives were non-steroidal anti-inflammatory drugs (naproxen, diclofenac 167 
or meloxicam) with gastric protection (omeprazole or ranitidine). Patients could decline or 168 
discontinue gout flare prophylaxis at any time. Any gout flares that occurred during the study were 169 
managed at the discretion of the patient’s local treating physician according to local guidelines. 170 
All patients had an annual follow-up visit during which serum urate, urea, creatinine and 171 
electrolytes, and liver function tests were measured. In addition, all patients had two-monthly 172 
follow-up contacts with the study team. Adverse events could be reported at any time by patients or 173 
health professionals. Record-linkage to centralised databases for records of hospitalisations, deaths 174 
and cancers was carried out at regular intervals during the study in the UK (Public Health Scotland 175 
and NHS Digital) and Denmark (Danish Health Data Board (Sundhedsdatastyrelsen)) (except for the 176 
last year of study follow-up in Denmark). Although significant attempts were made by the 177 
investigators to obtain similar record-linkage data in Sweden, this was not possible. Because the 178 
primary event rates were lower than predicted during the study, the trial recruitment period was 179 
extended beyond the two years originally planned and the follow-up period was also extended. 180 
Outcomes 181 
The primary outcome was the composite of: hospitalisation for non-fatal myocardial 182 
infarction/biomarker positive acute coronary syndrome, non-fatal stroke (whether reported to have 183 
been hospitalised, non-hospitalised or to have occurred during a hospitalisation) or death due to a 184 
cardiovascular event. 185 
10 
 
The secondary outcomes were: hospitalisation for non-fatal myocardial infarction/biomarker 186 
positive acute coronary syndrome; non-fatal stroke (whether reported to have been hospitalised, 187 
non-hospitalised or to have occurred during a hospitalisation); cardiovascular death; all-cause 188 
mortality; hospitalisation for heart failure; hospitalisation for unstable, new or worsening angina; 189 
hospitalisation for coronary revascularisation; hospitalisation for cerebral revascularisation; 190 
hospitalisation for transient ischaemic attack (TIA); hospitalisation for non-fatal cardiac arrest; 191 
hospitalisation for venous and peripheral arterial vascular thrombotic event; hospitalisation for 192 
arrhythmia with no evidence of ischaemia. 193 
Minor amendments to two components of the primary outcome were made during the trial – 194 
hospitalised stroke was amended to include strokes that were non-hospitalised or occurred during a 195 
hospitalisation, and myocardial infarction was updated to include myocardial infarction or biomarker 196 
positive acute coronary syndrome (which are largely considered to be the same outcome nowadays). 197 
An independent clinical events classification committee based at the University of Glasgow, whose 198 
members were unaware of the trial group assignments, assessed all the components of the primary 199 
composite outcome, secondary cardiovascular outcomes, and death; these events are defined in the 200 
clinical event definitions (appendix pp7-25). 201 
An exploratory efficacy endpoint was also included: the proportion of patients whose serum urate 202 
level was < 0·357 mmol/L (<6 mg/dL), and < 0·297 mmol/L (<5 mg/dL) after each year of treatment. 203 
Serious adverse events occurring during and up to 28 days after the end of the study were recorded 204 
unless participants had withdrawn consent. Gout flares and any treatment-related adverse events 205 
were also recorded. 206 
For adverse events that were potential study endpoints, more detailed information was collected 207 
from medical records and death certificates and an anonymised endpoint package was prepared for 208 
adjudication by an independent adjudication committee. 209 
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Statistical analysis 210 
It was calculated that 456 first primary events were required to show non-inferiority between the 211 
febuxostat and allopurinol treatment arms assuming a non-inferiority limit for the hazard ratio of 1·3 212 
with 80% power and a one-sided alpha of 0·025. The non-inferiority margin of 1·3 was selected and 213 
approved by the EMA as representing a minimal difference of clinical interest and was based on 214 
previous regulatory guidance and precedent. Previous and ongoing cardiovascular safety studies 215 
have used similar values which have been accepted by regulators, including cardiovascular safety 216 
trials of novel treatments for diabetes, trials comparing celecoxib with other non-steroidal anti-217 
inflammatory drugs and ongoing trials of novel renal treatments13-17. With an expected primary 218 
event rate of about 10% over three years in the allopurinol group based on events observed in 219 
observational databases, it was estimated that 2282 patients would be required in each treatment 220 
arm. Assuming a dropout rate of 20% from the on-treatment population, the enrolment of 2853 221 
patients in each treatment arm (5706 total) was predicted to provide the required number of 222 
primary events with an average follow-up period of 3 years. Baseline characteristics are shown 223 
according to treatment groups as means (SD) or median (IQR) for continuous variables and as 224 
numbers and percentages for categorical variables. 225 
 226 
All clinical outcomes were analysed on a time to first event basis using Cox proportional hazards 227 
models, with the exception of the frequency of flares of gout, for which all recurrent events were 228 
counted and analysed using a negative binomial regression model. All analyses were adjusted for the 229 
stratification variable and country and the treatment effect for febuxostat relative to allopurinol was 230 
estimated, reporting hazard ratios and 95% confidence intervals for the Cox models and incidence 231 
rate ratio and 95% confidence interval for the negative binomial model. P-values were calculated 232 
from Wald statistics. The primary analysis was an on-treatment (OT) analysis. The OT analyses 233 
censored follow-up after permanent discontinuation from original randomised therapy, death from 234 
any cause not included in the endpoint being considered, date of withdrawal of all consent to 235 
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participate further in the study or end of study (31 December, 2019), whichever occurred first. The 236 
intention to treat (ITT) analysis censored follow-up after death from any cause not included in the 237 
endpoint being considered, date of withdrawal of all consent to participate further in the study, or 238 
end of study, whichever occurred first. In the OT analyses, the primary outcome was assessed first in 239 
an OT non-inferiority analysis with a non-inferiority limit of 1·3. A supporting ITT analysis was 240 
conducted and, if non-inferiority was demonstrated in this analysis as well as the OT analysis, an ITT 241 
superiority analysis was carried out. This hierarchical testing process meant that there was no need 242 
for adjustment for multiple testing. Prespecified subgroup analyses were carried out for the primary 243 
endpoint. P values for the test of interaction between the variable defining the subgroup and 244 
randomised treatment allocation were calculated. Similar analyses were done for other time-to-245 
event secondary endpoints.   246 
Time to event curves are presented as cumulative incidence functions adjusting for the competing 247 
risk of deaths not included in the endpoint being plotted. 248 
Between treatment group differences in SUA levels were assessed annually using analysis of 249 
covariance, adjusting for baseline levels, the stratification variable, and country. 250 
The type I error rate was set at 2·5% (one-sided) for the one-sided non-inferiority analyses and at 5% 251 
for two-sided superiority analyses. No formal interim analyses were carried out and hence no P-252 
value penalties are required. No adjustments were made for the multiplicity of statistical 253 
comparisons. Hence, analyses other than for the primary endpoint should be considered 254 
exploratory. 255 
All validly randomised participants were included in the OT and ITT analyses. Safety analysis was 256 
done for all patients who took at least one dose of randomised medication. The incidence of serious 257 
treatment emergent adverse events is summarised by MedDRA system organ class for each 258 
treatment group.  259 
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Analyses and graphical displays were conducted using SAS for Windows version 9·4 and R version 260 
3·6·1. All cardiovascular outcomes were adjudicated by an independent clinical endpoint committee 261 
(appendix p34), except coronary revascularisation, cerebral revascularisation and TIA which were 262 
reviewed and classified by physicians at the University of Dundee. 263 
Trial safety was overseen by an independent data monitoring committee (appendix p34). This trial is 264 
registered with the EU Clinical Trials Register (EudraCT 2011-001883-23) and ISRCTN 265 
(ISRCTN72443728). 266 
Role of the funding source 267 
The study was an investigator-led trial sponsored by the University of Dundee and funded by 268 
Menarini. Menarini received support from Ipsen and Teijin Pharma Limited. The funder of the study 269 
had no role in study design, data collection, data analysis, data interpretation, writing of the 270 
manuscript or the decision to submit. TM, IM, IF and MR had full access to all the data in the study 271 
and TM had final responsibility for the decision to submit for publication. The study Clinical Co-272 
ordination Centre was MEMO Research at the University of Dundee and the study Data and 273 
Biostatistical Centre was at the Robertson Centre for Biostatistics at the University of Glasgow. Trial 274 
monitoring was carried out or subcontracted by the University of Dundee as study sponsor. 275 
Results 276 
From 20 December, 2011, to 17 October, 2017, 6603 patients consented to enrol in the trial and 277 
were assessed for eligibility; 475 patients were excluded before randomisation. Data for 14 278 
randomised patients and one non-randomised patient (all recruited at one UK site) were deleted 279 
from the study database following instruction by the sponsor because of concerns identified at a 280 
monitoring visit regarding the validity of consent and inclusion of these patients and their data. 281 
These 15 patients are excluded from all summaries and analyses. A total of 6128 patients were 282 
randomly assigned to receive febuxostat (n=3063) or allopurinol (n=3065; figure 1). The final 283 
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randomisation took place on 26 January, 2018. Patients stopped randomised treatment at the end of 284 
the trial, on 31 December, 2019. The study reached the end of its contracted period on 31 Dec 2019 285 
and the decision to end the trial then was made at a time when the number of adjudicated primary 286 
events that had occurred was still uncertain. The final lower than target number of primary events 287 
was due to uncertainty about whether some events had occurred ‘on treatment’ that was later 288 
clarified, and a lower than expected number of potential events for which information was still being 289 
gathered being adjudicated as positive events. Final record-linkage data and supporting information 290 
on endpoints resulted in the trial completion being the end of August 2020. Median follow-up time 291 
in the study was 1467 days [IQR 1029-2052] and median on-treatment follow-up period was 1324 292 
days [IQR 870-1919]. 293 
The two treatment groups were well balanced with respect to baseline characteristics (table 1) and 294 
baseline cardiovascular risk factors (appendix p26), with the exception of a small excess of history of 295 
diabetes mellitus (n=719 (23·5%) in the allopurinol group compared to n=661 (21·6%) in the 296 
febuxostat group). The mean age was 71·0 years (SD 6·4), 5225 (85·3%) were male and 6070 (99·1%) 297 
were white. 38·9% were recruited in Scotland, 27·3% in England, 31·7% in Denmark, and 2·1% in 298 
Sweden. 2046 patients (33·4%) had a history of cardiovascular disease (defined as myocardial 299 
infarction, cerebrovascular accident, transient ischaemic attack, acute coronary syndrome, coronary 300 
revascularisation, angina pectoris or heart failure). 1380 patients (22·5%) had a history of diabetes 301 
mellitus.  302 
A total of 3593 patients (58·6%) were taking statins, 2170 patients (35·4%) were taking antiplatelet 303 
agents, (including 1828 patients (29·8%) taking aspirin), and 2468 patients (40·3%) were taking an 304 
angiotensin-converting enzyme inhibitor at screening.  305 
The median duration of allopurinol therapy at time of screening was 6·0 years [IQR 2·1-14·0]. At the 306 
screening visit, most participants were taking 100mg-300mg daily dose of allopurinol (100mg (1951 307 
patients (31·8%)); 200mg (1066 patients (17·4%)); 300mg (2749 patients (44·9%)). In the allopurinol 308 
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lead-in phase, 2201 patients (35·9%) required an increase in allopurinol dose to reach EULAR target 309 
SUA during the allopurinol lead-in phase. The daily doses of allopurinol taken by participants 310 
immediately prior to randomisation are shown in appendix p27. The mean daily dose of allopurinol 311 
taken at the end of the lead-in allopurinol up-titration phase was 278mg in the allopurinol group and 312 
274mg in the febuxostat group.  At the end of allopurinol up-titration, 97·3% and 96·9% in the 313 
allopurinol and febuxostat groups respectively were at target urate. After randomisation, 97·5% of 314 
febuxostat daily doses were 80mg and 2·5% were 120mg. For allopurinol daily doses, 10·0% were 315 
100mg, 23·3% were 200mg, 50·9% were 300mg, 11·9% were 400 mg and 3·9% were 500-900 mg. 316 
The mean daily dose of febuxostat during the trial was 81mg. The mean daily dose of allopurinol 317 
during the trial was 279mg. 318 
 319 
In the primary on-treatment analysis, febuxostat therapy was non-inferior to allopurinol therapy for 320 
incidence of the primary endpoint (172 patients assigned to febuxostat [1·72 events per 100 patient 321 
years]) compared with 241 patients assigned to allopurinol [2·05 events per 100 patient years]); 322 
adjusted hazard ratio 0·85 [95% CI 0·70-1·03], p<0·001) (figure 2a). The ITT analysis confirmed non-323 
inferiority of febuxostat (p<0·001) (figure 2b)). Superiority of febuxostat for the primary outcome 324 
was not demonstrated (p=0·19). Results obtained in on-treatment and intention to treat analyses for 325 
all-cause mortality (figure 3a and b), cardiovascular death (figure 3c and d)), and for the other 326 
secondary outcomes are presented in tables 2 and 3. In the on-treatment analysis, the upper limit of 327 
the hazard ratio for all-cause mortality was below 1·0. There were 174 deaths (1·44/100 patient 328 
years) in the allopurinol group and 108 (1·06/100 patient years) in the febuxostat group, HR (95%CI), 329 
0·75 (0·59, 0·95). In the intention to treat analysis, there were 263 deaths (2·05/100 patient years) in 330 
the allopurinol group versus 222 (1·73/100 patient years) in the febuxostat group, HR (95%CI) 0·84 331 
(0·71, 1·01). In contrast there was a nominally significant increase in hospitalisation for arrhythmia 332 
with no evidence of ischaemia, with 49 patients (0·385/100 patient years) with an event in the 333 
allopurinol group versus 74 patients (0·583/100 patient years) in the febuxostat group. 334 
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A total of 28 pre-specified analyses were carried out based on subgroups according to baseline 335 
characteristics (appendix pp40-43). Only one subgroup analysis reached statistical significance in the 336 
interaction test (on-treatment p=0·001; intention to treat p=0·003). This was for the subgroups 337 
defined by pre-randomisation urate levels < 0·297 mmol/L and ≥ 0·297 mmol/L. There was a 338 
nominally significant reduction in risk in the febuxostat arm compared to the allopurinol arm in the < 339 
0·297 mmol/L urate subgroup and no statistically significant difference between the two groups in 340 
the ≥ 0·297 mmol/L subgroup for the primary outcome. The analysis for the primary outcome in the 341 
subgroup of patients with a history of MI, stroke or acute coronary syndrome showed no significant 342 
difference between treatment groups (allopurinol n=83 (11·8%), febuxostat n=65 (9·5%); adjusted 343 
HR 1.02 (95% CI 0·74-1·42); p=0.202 (on treatment analysis). In the intention to treat analysis for this 344 
subgroup results were similar (allopurinol n=102 (14·5%), febuxostat n=103 (15·1%); adjusted HR 345 
1·07 (95% CI 0·81-1·41); p=0·119). On the request of a reviewer, an analysis of the composite 346 
primary endpoint replacing CV death with all-cause death (on-treatment and intention to treat) and 347 
an on-treatment analysis of the same endpoint but extending the on-treatment period by 90 days 348 
are presented in the supplementary appendix (pp36-37) The results of these additional analyses 349 
were consistent with the main results presented. An on-treatment analysis of the composite 350 
outcome of all-cause mortality, non-fatal myocardial infarction/biomarker positive acute coronary 351 
syndrome or non-fatal stroke, with additional adjustment for age, sex, low density lipoprotein and 352 
high density lipoprotein cholesterol levels, high sensitivity troponin I levels, systolic blood pressure, 353 
smoking status and histories (yes/no) of each of diabetes, hypertension and cardiovascular disease is 354 
also presented in the supplementary appendix (p38). 355 
There was a greater reduction in urate levels on febuxostat treatment compared to allopurinol 356 
treatment. The changes from baseline were compared statistically between the two groups at years 357 
1-7. There were significant differences between the two groups (p<0·0001) in each year with mean 358 
differences greater than 0·08 mmol/L for years one to six. After randomisation, 1044 patients in the 359 
allopurinol arm experienced at least one gout flare compared to 1017 patients in the febuxostat 360 
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arm. The rates of gout flares were 19·85 gout flares/100 patient years for allopurinol and 17·95 gout 361 
flares/100 patient years for febuxostat. 362 
A total of 3050 patients in the allopurinol group and 3001 patients in the febuxostat group took at 363 
least one dose of randomised study medication and were included in the safety population 364 
(n=6051). In the febuxostat group, 973 patients [32·4%] discontinued randomised therapy compared 365 
with 503 patients [16·5%] on allopurinol. The excess withdrawals and withdrawals from treatment in 366 
the febuxostat arm occurred in the first year of follow-up, with most occurring in the first six months 367 
(appendix pp38-39). Colchicine was the most commonly dispensed gout flare prophylaxis and was 368 
dispensed to 1603 patients in the allopurinol group and 2223 patients in the febuxostat group 369 
(appendix p28).  370 
A total of 263 (8·6%) patients died and 1812 (59·4%) experienced at least one serious adverse event 371 
in the allopurinol group compared to 222 (7·2%) and 1720 (57·3%) in the febuxostat group (Table 4 372 
and appendix p30, p32). Differences were seen in the incidence of endocrine disorders, and 373 
neoplasms (benign, malignant and unspecified (including cysts and polyps)) between treatment 374 
groups. The upper limit of normal for creatinine was 106 µmol/L in males and 80 µmol/L in females. 375 
31% of patients had at least one value above this limit in the allopurinol group and 34% in the 376 
febuxostat group. Only 24 patients had serious adverse events that were considered treatment-377 
related, 19 in the febuxostat group and 5 in the allopurinol group. There were 28 treatment-related 378 
serious adverse events in total. The most obvious difference between treatment groups for 379 
treatment-related serious adverse events was for gastrointestinal disorders (8 for the febuxostat 380 
group versus 1 for the allopurinol group). In the allopurinol group, the five treatment-related serious 381 
adverse events were angina (two cases), thrombocytopenia, dyspepsia and arthralgia (all recovered). 382 
In the febuxostat group, the 23 treatment-related serious adverse events in 19 patients were 383 
pancreatitis (five episodes in four patients; one  patient recovered, two recovered with sequelae; 384 
one patient had pancreatitis that recovered, then had a further episode of pancreatitis with 385 
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gastrointestinal perforation, circulatory collapse and death), diarrhoea (three cases, all recovered, 386 
one additionally associated with acute renal failure which recovered), atrial fibrillation (three cases, 387 
two recovered, one not recovered), cholecystitis (two cases, one recovered, one recovered with 388 
sequelae). The other treatment-related serious adverse events in the febuxostat group were single 389 
cases of haematuria and non-cardiac chest pain (recovered), and worsening renal failure, abnormal 390 
liver function tests, rotator cuff syndrome and pneumonia (recovered with sequelae). Because all 391 
patients were taking allopurinol at baseline, those randomised to the allopurinol group were 392 
inherently less likely to experience treatment-related serious adverse events during the trial, than 393 
those allocated to the febuxostat group (a novel treatment). More patients overall were reported to 394 
be suffering from a malignant neoplasm in the allopurinol arm 384 (12·6%) versus 322 (10·7%) in the 395 
febuxostat arm (appendix p31). In the 28 day period following the end of the study, four deaths 396 
were reported in each treatment group. 397 
Discussion 398 
This FAST study has clearly demonstrated that in more than 6000 patients with gout receiving ULT 399 
with a xanthine oxidase inhibitor at doses designed to lower the urate to EULAR target levels 400 
<0.357mmol/L for up to seven years, febuxostat was non-inferior to allopurinol with regard to the 401 
occurrence of major cardiovascular outcomes comprising the primary outcome of hospitalisation for 402 
non-fatal myocardial infarction/biomarker positive acute coronary syndrome, non-fatal stroke or 403 
death due to a cardiovascular event. This was demonstrated in both the primary on-treatment and 404 
intention to treat analyses. Importantly, there was no signal of increased mortality, with a lower rate 405 
of all-cause deaths and cardiovascular deaths reported in the febuxostat group than in the 406 
allopurinol group. This contrasts with the findings of the North American Cardiovascular Safety of 407 
Febuxostat or Allopurinol in Patients with Gout trial (CARES) which reported that in patients with 408 
gout and established cardiovascular comorbidities at baseline, while febuxostat was non-inferior to 409 
allopurinol with respect to rates of the primary endpoint of the study (a composite of death from 410 
cardiovascular causes, myocardial infarction, stroke, or unstable angina with urgent 411 
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revascularisation), the rates of the secondary outcomes of adverse cardiovascular outcomes, all-412 
cause death and cardiovascular death were significantly higher with febuxostat than with 413 
allopurinol.17  However, when efforts were made to trace patients in CARES lost to follow-up, this 414 
mortality difference was no longer seen, and it was unclear why increased mortality was associated 415 
with lower doses of febuxostat. This could simply have been information bias caused by the inability 416 
to adequately follow up those who withdrew from CARES. The supporting analyses of CARES where 417 
private investigators followed up the vital status of those who withdrew found that the signal of 418 
increased mortality was no longer significant and supports this view.  419 
Although of similar size, there are several differences between the CARES trial and the FAST trial. All 420 
patients in CARES had established cardiovascular disease, while only 33% of patients in FAST had 421 
cardiovascular disease at baseline. CARES included patients with severe heart failure who might have 422 
particularly poor cardiovascular prognosis, whereas FAST excluded patients with NYHA III or IV heart 423 
failure. The prevalence of tophi was greater in the CARES population, suggesting more severe gout at 424 
baseline. CARES allowed inclusion of newly treated patients, while FAST only recruited patients who 425 
were already established on allopurinol therapy and may therefore have had a lower urate crystal 426 
burden, which might be important for cardiovascular risk. To what extent the results of FAST are 427 
generalisable to patients with gout who have not previously been treated with ULT, or to patients 428 
with severe heart failure is not clear. The doses of randomised medication were different in the two 429 
trials, with a lower dose of febuxostat being used in CARES (40-80mg daily) compared with FAST 430 
(80mg-120mg daily) and the range of doses of allopurinol differed (200-600mg daily in CARES; 100-431 
900mg daily in FAST), reflecting the different dose ranges for the two XOIs approved by regulatory 432 
agencies in North America and Europe. In the CARES trial, 56·6% of patients discontinued 433 
randomised treatment prematurely and 45·0% of patients withdrew and did not complete all trial 434 
visits and were therefore not followed up until the end of the trial. In the FAST study, there were 435 
lower rates of treatment discontinuation (16·5% in the allopurinol group and 32·4% in the febuxostat 436 
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group) and much better rates of patient follow up with only 5·8% of patients in FAST withdrawing 437 
from all follow up. 438 
The results of the CARES study led to regulators issuing alerts from 2017 onwards and subsequently 439 
changing prescribing advice for febuxostat and recommending that treatment with febuxostat 440 
should be avoided in patients with pre-existing major cardiovascular diseases (e.g. myocardial 441 
infarction, stroke or unstable angina), unless no other therapeutic options are appropriate. At the 442 
time this advice was released in Europe and the UK, the Medicines and Healthcare Regulatory 443 
Agency (MHRA) requested that the FAST investigators should provide an updated risk-benefit 444 
assessment about whether the study should continue. An independent risk-benefit assessment led 445 
to the MHRA making the recommendation in 2018 that FAST should continue unchanged. However, 446 
it is likely that the regulatory advice released to healthcare professionals at this time may have 447 
increased withdrawals from randomised medication in the febuxostat arm of the study. Notably, no 448 
increased risk of adverse cardiovascular events was found in the FAST subgroup of patients with 449 
prior MI, stroke or acute coronary syndrome, who were very similar to the patients included in the 450 
CARES study. 451 
The FAST study finished underpowered for the required number of primary events, with 413 events 452 
instead of the planned target of 456 events. The lower number of primary events will have resulted 453 
in only a modest reduction in statistical power from 80% to approximately 77% to exclude a non-454 
inferiority limit of 1·3, or alternatively, 80% power to exclude a non-inferiority limit of 1·315.  455 
The primary analysis of FAST, endorsed by the EMA, was an on-treatment rather than intention-to-456 
treat analysis, as is commonly the case in a non-inferiority safety trial. In such trials, on-treatment 457 
analysis results in a comparison that is undiluted by periods when the medications under 458 
investigation were not taken. In FAST, our research pharmacy had regular contact with all trial 459 
participants about adherence so our ascertainment of exposure to randomised medications was 460 
good. However, an on-treatment analysis may not provide a true unbiased analysis of the 461 
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randomised population if there are differential discontinuation rates, as indeed there were in FAST, 462 
with higher discontinuation rates and earlier discontinuations of febuxostat than allopurinol. This 463 
could have been influenced by the higher use of colchicine in patients randomised to febuxostat and 464 
the fact that switching from any established drug therapy to a new drug therapy usually results in 465 
more discontinuations in trials. For this reason, a supporting ITT analysis was also done. Because we 466 
were able to follow up patients until the end of the trial by telephone and other personal contact 467 
and by record-linkage to national hospitalisation and death records (except for the small proportion 468 
who withdrew completely), our ascertainment of outcomes in the ITT analysis was very good. Both 469 
analyses provided similar mortality findings. 470 
Although an association between serum urate concentrations and cardiovascular disease is well 471 
established from numerous observational studies the hypothesis that hyperuricaemia has a direct 472 
causal role in the aetiopathogenesis of comorbid cardiovascular disease remains controversial and is 473 
not supported by Mendelian randomisation studies.18,19  474 
 475 
Colchicine use was greater in the febuxostat group, probably because more patients switching 476 
therapy to febuxostat chose to accept gout flare prophylaxis than those continuing on allopurinol. 477 
Although some recent trials have demonstrated that treatment with colchicine improved outcomes 478 
in patients with recent myocardial infarction, and chronic coronary disease, published evidence that 479 
treatment with colchicine may be associated with improvements in cardiovascular outcomes has 480 
been inconsistent.20-23 In FAST, while prophylaxis against flares of gout was offered to all patients, 481 
only some accepted it, those who took it mainly did so at the very beginning of the trial, and it is 482 
likely that some patients chose to take it for less than the six months provided. It is unlikely that the 483 
relatively short-term administration of low dose colchicine or NSAIDs as prophylaxis, or any 484 
differences in concomitant use of colchicine or NSAIDs, even with the imbalances between 485 
treatment groups, had any major effect on the long-term outcomes of FAST. A new figure has been 486 
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added to the supplementary appendix (Figure S5, pp50-51) to show the effects of prophylaxis or 487 
concomitant use of NSAIDs or colchicine. 488 
As neither the FAST nor CARES trial had a placebo arm for comparison against active treatment with 489 
XOI, it is possible that either or both XOIs may actually protect patients with gout against 490 
cardiovascular disease and mortality. Certainly, the cardiovascular event rates in the FAST study 491 
were lower than anticipated. A large randomised trial comparing allopurinol 600mg daily therapy 492 
versus usual care, the ALL-HEART study,24 is currently underway in the UK to determine if allopurinol 493 
has a beneficial effect on major cardiovascular outcomes in patients with ischaemic heart disease 494 
(IHD). Should allopurinol be of benefit in IHD, a case could be made to carry out a randomised trial of 495 
febuxostat vs usual care or placebo in patients with cardiovascular disease.  496 
Other findings of FAST may deserve further research. One possibility is to investigate the findings of 497 
numerically higher non-CV deaths and malignancies with allopurinol than febuxostat. Another is to 498 
investigate the higher rate of hospitalisations for arrhythmias without evidence of ischaemia found 499 
in FAST.  500 
In summary, we found that febuxostat 80-120mg was non-inferior to allopurinol 100-900mg with 501 
respect to its impact on adverse cardiovascular events. In contrast to a previous large study, we 502 
found no signal of increased all-cause or cardiovascular mortality with febuxostat. In the light of 503 
these findings, regulatory advice to avoid the use of febuxostat in patients with cardiovascular 504 
disease should be reconsidered and modified. 505 
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